Literature DB >> 15483098

The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome.

Francesco Orio1, Stefano Palomba, Teresa Cascella, Sebastiano Di Biase, Francesco Manguso, Libuse Tauchmanovà, Luciano G Nardo, Donato Labella, Silvia Savastano, Tiziana Russo, Fulvio Zullo, Annamaria Colao, Gaetano Lombardi.   

Abstract

White blood cell (WBC) count is a known risk factor for atherosclerotic vascular disease in adult women. Polycystic ovary syndrome (PCOS) is potentially a risk factor for atherosclerosis and cardiovascular disease. The aim of the present study was to investigate leukocyte count in PCOS. One hundred and fifty PCOS women matched for age and body mass index with 150 healthy women were enrolled. WBC count, C-reactive protein, and a complete anthropometrical, metabolic, and hormonal evaluation were performed in both groups. Serum insulin, glucose level, and lipid profile were also measured in each subject. WBC count was significantly higher (P < 0.0001) in PCOS with (interquartile range in parentheses) 7260 (393) cells/mm(3), compared with controls with 5220 (210) cells/mm(3). C-reactive protein levels were significantly increased (P < 0.0001) in PCOS with 2 (1) mg/liter compared with healthy women with 0.7 (0.8) mg/liter. In both groups, there was a significant (P < 0.0001) linear correlation between WBC count and homeostasis model assessment score (PCOS, r = 0.94; controls, r = 0.91). Multiple linear regression analysis showed that other hormone levels are not predictors of leukocyte count both in PCOS and control women. In conclusion, our data demonstrate that PCOS women have an increased WBC count that correlates with homeostasis model assessment values.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15483098     DOI: 10.1210/jc.2004-0628

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  43 in total

Review 1.  The metabolic syndrome in polycystic ovary syndrome.

Authors:  P A Essah; J E Nestler
Journal:  J Endocrinol Invest       Date:  2006-03       Impact factor: 4.256

2.  The inflammatory markers in polycystic ovary syndrome: association with obesity and IVF outcomes.

Authors:  Y Çakıroğlu; F Vural; B Vural
Journal:  J Endocrinol Invest       Date:  2016-03-15       Impact factor: 4.256

Review 3.  Inflammation and Human Ovarian Follicular Dynamics.

Authors:  Christina E Boots; Emily S Jungheim
Journal:  Semin Reprod Med       Date:  2015-07-01       Impact factor: 1.303

4.  Is PCOS an inflammatory process?

Authors:  Antoni J Duleba; Anuja Dokras
Journal:  Fertil Steril       Date:  2012-01       Impact factor: 7.329

Review 5.  Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis.

Authors:  Héctor F Escobar-Morreale; Manuel Luque-Ramírez; Frank González
Journal:  Fertil Steril       Date:  2010-12-17       Impact factor: 7.329

6.  Higher circulating leukocytes in women with PCOS is reversed by aerobic exercise.

Authors:  Jeffrey D Covington; Charmaine S Tam; Magdalena Pasarica; Leanne M Redman
Journal:  Biochimie       Date:  2014-11-12       Impact factor: 4.079

Review 7.  Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment.

Authors:  Héctor F Escobar-Morreale
Journal:  Nat Rev Endocrinol       Date:  2018-03-23       Impact factor: 43.330

8.  Immunophenotypic profile of leukocytes in hyperandrogenemic female rat an animal model of polycystic ovary syndrome.

Authors:  Mohadetheh Moulana
Journal:  Life Sci       Date:  2019-01-29       Impact factor: 5.037

Review 9.  Mediators of inflammation in polycystic ovary syndrome in relation to adiposity.

Authors:  Thozhukat Sathyapalan; Stephen L Atkin
Journal:  Mediators Inflamm       Date:  2010-04-08       Impact factor: 4.711

10.  Endocrine and Metabolic Profile of Different Phenotypes of Polycystic Ovarian Syndrome.

Authors:  Saxena Pikee; Singh Shivani; Bhattacharjee Jayshree
Journal:  J Obstet Gynaecol India       Date:  2016-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.